Resynchronization-defibrillation for heart failure shows long-term benefits
Cardiology Update
JANUARY 22, 2024
The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). However, the impact of CRT on long-term survival remained uncertain. [link] Patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and a QRS du
Let's personalize your content